CYP2C9
CYP2C9
Main page
1804332

CYP2C9

logo
Community Hub0 subscribers
Read side by side
CYP2C9
View on Wikipedia
from Wikipedia

CYP2C9
Available structures
PDBHuman UniProt search: PDBe RCSB
Identifiers
AliasesCYP2C9, CPC9, CYP2C, CYP2C10, CYPIIC9, P450IIC9, cytochrome P450 family 2 subfamily C member 9, Cytochrome P450 2C9, P450-2C9
External IDsOMIM: 601130; MGI: 1919553; HomoloGene: 133566; GeneCards: CYP2C9; OMA:CYP2C9 - orthologs
EC number1.14.14.51
Orthologs
SpeciesHumanMouse
Entrez

1559

72303

Ensembl

ENSG00000138109

ENSMUSG00000067231

UniProt

P11712

n/a

RefSeq (mRNA)

NM_000771

NM_028191

RefSeq (protein)

NP_000762

n/a

Location (UCSC)Chr 10: 94.94 – 94.99 MbChr 19: 39.05 – 39.08 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Cytochrome P450 family 2 subfamily C member 9 (abbreviated CYP2C9) is an enzyme protein. The enzyme is involved in the metabolism, by oxidation, of both xenobiotics, including drugs, and endogenous compounds, including fatty acids. In humans, the protein is encoded by the CYP2C9 gene.[5][6] The gene is highly polymorphic, which affects the efficiency of the metabolism by the enzyme.[7]

Function

[edit]

CYP2C9 is a crucial cytochrome P450 enzyme, which plays a significant role in the metabolism, by oxidation, of both xenobiotic and endogenous compounds.[7] CYP2C9 makes up about 18% of the cytochrome P450 protein in liver microsomes. The protein is mainly expressed in the liver, duodenum, and small intestine.[7] About 100 therapeutic drugs are metabolized by CYP2C9, including drugs with a narrow therapeutic index such as warfarin and phenytoin, and other routinely prescribed drugs such as acenocoumarol, tolbutamide, losartan, glipizide, and some nonsteroidal anti-inflammatory drugs. By contrast, the known extrahepatic CYP2C9 often metabolizes important endogenous compounds such as serotonin and, owing to its epoxygenase activity, various polyunsaturated fatty acids, converting these fatty acids to a wide range of biologically active products.[8][9]

In particular, CYP2C9 metabolizes arachidonic acid to the following eicosatrienoic acid epoxide (EETs) stereoisomer sets: 5R,6S-epoxy-8Z,11Z,14Z-eicosatetraenoic and 5S,6R-epoxy-8Z,11Z,14Z-eicosatetraenoic acids; 11R,12S-epoxy-8Z,11Z,14Z-eicosatetraenoic and 11S,12R-epoxy-5Z,8Z,14Z-eicosatetraenoic acids; and 14R,15S-epoxy-5Z,8Z,11Z-eicosatetraenoic and 14S,15R-epoxy-5Z,8Z,11Z-eicosatetraenoic acids. It likewise metabolizes docosahexaenoic acid to epoxydocosapentaenoic acids (EDPs; primarily 19,20-epoxy-eicosapentaenoic acid isomers [i.e. 10,11-EDPs]) and eicosapentaenoic acid to epoxyeicosatetraenoic acids (EEQs, primarily 17,18-EEQ and 14,15-EEQ isomers).[10] Animal models and a limited number of human studies implicate these epoxides in reducing hypertension; protecting against myocardial infarction and other insults to the heart; promoting the growth and metastasis of certain cancers; inhibiting inflammation; stimulating blood vessel formation; and possessing a variety of actions on neural tissues including modulating neurohormone release and blocking pain perception (see epoxyeicosatrienoic acid and epoxygenase).[9]

In vitro studies on human and animal cells and tissues and in vivo animal model studies indicate that certain EDPs and EEQs (16,17-EDPs, 19,20-EDPs, 17,18-EEQs have been most often examined) have actions which often oppose those of another product of CYP450 enzymes (e.g. CYP4A1, CYP4A11, CYP4F2, CYP4F3A, and CYP4F3B) viz., 20-Hydroxyeicosatetraenoic acid (20-HETE), principally in the areas of blood pressure regulation, blood vessel thrombosis, and cancer growth (see 20-Hydroxyeicosatetraenoic acid, epoxyeicosatetraenoic acid, and epoxydocosapentaenoic acid sections on activities and clinical significance). Such studies also indicate that the eicosapentaenoic acids and EEQs are: 1) more potent than EETs in decreasing hypertension and pain perception; 2) more potent than or equal in potency to the EETs in suppressing inflammation; and 3) act oppositely from the EETs in that they inhibit angiogenesis, endothelial cell migration, endothelial cell proliferation, and the growth and metastasis of human breast and prostate cancer cell lines whereas EETs have stimulatory effects in each of these systems.[11][12][13][14] Consumption of omega-3 fatty acid-rich diets dramatically raises the serum and tissue levels of EDPs and EEQs in animals as well as humans, and in humans is by far the most prominent change in the profile of polyunsaturated fatty acids metabolites caused by dietary omega-3 fatty acids.[11][14][15]

CYP2C9 may also metabolize linoleic acid to the potentially very toxic products, coronaric acid (also termed leukotoxin) and vernolic acid (also termed isoleukotoxin); these linoleic acid epoxides cause multiple organ failure and acute respiratory distress in animal models and may contribute to these syndromes in humans.[9]

Pharmacogenomics

[edit]

The CYP2C9 gene is highly polymorphic.[16] At least 20 single nucleotide polymorphisms (SNPs) have been reported to have functional evidence of altered enzyme activity.[16] In fact, adverse drug reactions (ADRs) often result from unanticipated changes in CYP2C9 enzyme activity secondary to genetic polymorphisms. Especially for CYP2C9 substrates such as warfarin and phenytoin, diminished metabolic capacity because of genetic polymorphisms or drug-drug interactions can lead to toxicity at normal therapeutic doses.[17][18] Information about how human genetic variation of CYP2C9 affects response to medications can be found in databases such PharmGKB,[19] Clinical Pharmacogenetics Implementation Consortium (CPIC).[20]

The label CYP2C9*1 is assigned by the Pharmacogene Variation Consortium (PharmVar) to the most commonly observed human gene variant.[21] Other relevant variants are cataloged by PharmVar under consecutive numbers, which are written after an asterisk (star) character to form an allele label.[22][23] The two most well-characterized variant alleles are CYP2C9*2 (NM_000771.3:c.430C>T, p.Arg144Cys, rs1799853) and CYP2C9*3 (NM_000771.3:c.1075A>C, p. Ile359Leu, rs1057910),[24] causing reductions in enzyme activity of 30% and 80%, respectively.[16]

Metabolizer phenotypes

[edit]

On the basis of their ability to metabolize CYP2C9 substrates, individuals can be categorized by groups. The carriers of homozygous CYP2C9*1 variant, i.e. of the *1/*1 genotype, are designated extensive metabolizers (EM), or normal metabolizers.[25] The carriers of the CYP2C9*2 or CYP2C9*3 alleles in a heterozygous state, i.e. just one of these alleles (*1/*2, *1/*3) are designated intermediate metabolizers (IM), and those carrying two of these alleles, i.e. homozygous (*2/*3, *2/*2 or *3/*3) – poor metabolizers (PM).[26][27] As a result, the metabolic ratio – the ratio of unchanged drug to metabolite – is higher in PMs.

A study of the ability to metabolize warfarin among the carriers of the most well-characterized CYP2C9 genotypes (*1, *2 and *3), expressed as a percentage of the mean dose in patients with wild-type alleles (*1/*1), concluded that the mean warfarin maintenance dose was 92% in *1/*2, 74% in *1/*3, 63% in *2/*3, 61% in *2/*2 and 34% in 3/*3.[28]

CYP2C9*3 reflects an Ile359-Leu (I359L) change in the amino acid sequence,[29] and also has reduced catalytic activity compared with the wild type (CYP2C9*1) for substrates other than warfarin.[24] Its prevalence varies with race as:

Allele frequencies (%) of CYP2C9 polymorphism
African-American Black-African Pygmy Asian Caucasian
CYP2C9*3 2.0 0–2.3 0 1.1–3.6 3.3–16.2

Test panels of variant alleles

[edit]

The Association for Molecular Pathology Pharmacogenomics (PGx) Working Group in 2019 has recommended a minimum panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) to be included in assays for CYP2C9 testing.

CYP2C9 variant alleles recommended as Tier 1 by the PGx Working Group include CYP2C9 *2, *3, *5, *6, *8, and *11. This recommendation was based on their well-established functional effects on CYP2C9 activity and drug response availability of reference materials, and their appreciable allele frequencies in major ethnic groups.

The following CYP2C9 alleles are recommended for inclusion in tier 2: CYP2C9*12, *13, and *15.[16]

CYP2C9*13 is defined by a missense variant in exon 2 (NM_000771.3:c.269T>C, p. Leu90Pro, rs72558187).[16] CYP2C9*13 prevalence is approximately 1% in the Asian population,[30] but in Caucasians this variant prevalence is almost zero.[31] This variant is caused by a T269C mutation in the CYP2C9 gene which in turn results in the substitution of leucine at position-90 with proline (L90P) at the product enzyme protein. This residue is near the access point for substrates and the L90P mutation causes lower affinity and hence slower metabolism of several drugs that are metabolized CYP2C9 by such as diclofenac and flurbiprofen.[30] However, this variant is not included in the tier 1 recommendations of the PGx Working Group because of its very low multiethnic minor allele frequency and a lack of currently available reference materials.[16] As of 2020 the evidence level for CYP2C9*13 in the PharmVar database is limited, comparing to the tier 1 alleles, for which the evidence level is definitive.[21]

Additional variants

[edit]

Not all clinically significant genetic variant alleles have been registered by PharmVar. For example, in a 2017 study, the variant rs2860905 showed stronger association with warfarin sensitivity (<4 mg/day) than common variants CYP2C9*2 and CYP2C9*3.[32] Allele A (23% global frequency) is associated with a decreased dose of warfarin as compared to the allele G (77% global frequency). Another variant, rs4917639, according to a 2009 study, has a strong effect on warfarin sensitivity, almost the same as if CYP2C9*2 and CYP2C9*3 were combined into a single allele.[33] The C allele at rs4917639 has 19% global frequency. Patients with the CC or CA genotype may require decreased dose of warfarin as compared to patients with the wild-type AA genotype.[34] Another variant, rs7089580 with T allele having 14% global frequency, is associated with increased CYP2C9 gene expression. Carriers of AT and TT genotypes at rs7089580 had increased CYP2C9 expression levels compared to wild-type AA genotype. Increased gene expression due to rs7089580 T allele leads to an increased rate of warfarin metabolism and increased warfarin dose requirements. In a study published in 2014, the AT genotype showed slightly higher expression than TT, but both much higher than AA.[35] Another variant, rs1934969 (in studies of 2012 and 2014) have been shown to affect the ability to metabolize losartan: carriers of the TT genotype have increased CYP2C9 hydroxylation capacity for losartan comparing to AA genotype, and, as a result, the lower metabolic ratio of losartan, i.e., faster losartan metabolism.[36][37]

Ligands

[edit]

Most inhibitors of CYP2C9 are competitive inhibitors. Noncompetitive inhibitors of CYP2C9 include nifedipine,[38][39] phenethyl isothiocyanate,[40] medroxyprogesterone acetate[41] and 6-hydroxyflavone. It was indicated that the noncompetitive binding site of 6-hydroxyflavone is the reported allosteric binding site of the CYP2C9 enzyme.[42]

Following is a table of selected substrates, inducers and inhibitors of CYP2C9. Where classes of agents are listed, there may be exceptions within the class.

Inhibitors of CYP2C9 can be classified by their potency, such as:

  • Strong being one that causes at least a 5-fold increase in the plasma AUC values, or more than 80% decrease in clearance.[43]
  • Moderate being one that causes at least a 2-fold increase in the plasma AUC values, or a 50–80% decrease in clearance.[43]
  • Weak being one that causes at least a 1.25-fold but less than 2-fold increase in the plasma AUC values, or 20–50% decrease in clearance.[43][44]
Selected inducers, inhibitors and substrates of CYP2C9
Substrates Inhibitors Inducers

Strong

Moderate

Weak

Unspecified potency

Strong

Weak

Epoxygenase activity

[edit]

CYP2C9 attacks various long-chain polyunsaturated fatty acids at their double (i.e. alkene) bonds to form epoxide products that act as signaling molecules. It along with CYP2C8, CYP2C19, CYP2J2, and possibly CYP2S1 are the principle enzymes which metabolizes 1) arachidonic acid to various epoxyeicosatrienoic acids (also termed EETs); 2) linoleic acid to 9,10-epoxy-octadecenoic acids (also termed coronaric acid, linoleic acid 9,10-oxide, or leukotoxin) and 12,13-epoxy-octadecenoic acids (also termed vernolic acid, linoleic acid 12,13-oxide, or isoleukotoxin); 3) docosahexaenoic acid to various epoxydocosapentaenoic acids (also termed EDPs); and 4) eicosapentaenoic acid to various epoxyeicosatetraenoic acids (also termed EEQs).[9] Animal model studies implicate these epoxides in regulating: hypertension, myocardial infarction and other insults to the heart, the growth of various cancers, inflammation, blood vessel formation, and pain perception; limited studies suggest but have not proven that these epoxides may function similarly in humans (see Epoxyeicosatrienoic acid and Epoxygenase).[9] Since the consumption of omega-3 fatty acid-rich diets dramatically raises the serum and tissue levels of the EDP and EEQ metabolites of the omega-3 fatty acid, i.e. docosahexaenoic and eicosapentaenoic acids, in animals and humans and in humans is the most prominent change in the profile of polyunsaturated fatty acids metabolites caused by dietary omega-3 fatty acids, eicosapentaenoic acids and EEQs may be responsible for at least some of the beneficial effects ascribed to dietary omega-3 fatty acids.[11][14][15]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

CYP2C9

View on Grokipedia
from Grokipedia
CYP2C9 is a gene located on chromosome 10q23.33 that encodes a cytochrome P450 monooxygenase enzyme belonging to the CYP2C subfamily, which catalyzes the oxidation of various substrates including drugs, steroid hormones, fatty acids, and endogenous compounds like arachidonic acid.[1] This enzyme is primarily expressed in the liver and gastrointestinal tract, where it constitutes approximately 20% of the hepatic cytochrome P450 protein content and plays a major role in the metabolism of up to 15% of clinically used small-molecule drugs.[2][3] As one of the most important drug-metabolizing enzymes in humans, CYP2C9 is responsible for the biotransformation of key therapeutic agents such as the anticoagulant warfarin (particularly its more potent S-enantiomer), nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and celecoxib, anticonvulsants like phenytoin, and oral hypoglycemics like tolbutamide.[4][5][2] Its activity is crucial for determining the pharmacokinetics, efficacy, and safety of these narrow therapeutic index drugs, with inhibition or induction by other substances potentially leading to adverse drug interactions.[6] For instance, CYP2C9 converts S-warfarin to inactive hydroxy metabolites, and reduced enzyme function can prolong anticoagulation effects, increasing bleeding risk.[7] The CYP2C9 gene is highly polymorphic, with over 85 identified variants that influence enzyme activity and expression levels, contributing to inter-individual variability in drug response.[8][9] Common loss-of-function alleles include CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910), which reduce metabolic activity by 30-80% and are more prevalent in certain populations, such as Europeans for 2 and 3, and Africans for rarer variants like 5, 6, 8, and 11.[2][4] Homozygotes for these reduced-activity alleles may require substantial dose reductions—up to 80% for warfarin—to avoid toxicity, and pharmacogenomic guidelines now incorporate CYP2C9 genotyping for personalized dosing algorithms.[4][2] Beyond pharmacology, CYP2C9 contributes to the biosynthesis of cholesterol, steroids, and other lipids, and its variants have been linked to conditions like warfarin sensitivity and potential risks for cardiovascular or metabolic disorders, underscoring its broader physiological significance.[1][4] Ongoing research focuses on characterizing rare variants and their impact on drug safety, particularly in diverse populations, to advance precision medicine.[3][8]

Gene and Expression

Gene Location and Structure

The CYP2C9 gene is situated on the long arm of human chromosome 10 at the cytogenetic band 10q23.33.[1] This location places it within a cluster of cytochrome P450 genes on chromosome 10q23.33, reflecting the genomic organization of the CYP2C subfamily.[1] The gene spans approximately 51 kb of genomic DNA, encompassing 9 exons that encode the mature protein.[1] Introns interrupt the coding sequence, with exon 1 containing the majority of the 5' untranslated region and the initiation codon.[1] The promoter region of CYP2C9 includes key regulatory elements essential for its transcriptional control, particularly two proximal direct repeat 1 (DR-1) motifs that serve as binding sites for hepatocyte nuclear factor 4α (HNF4α), located at -185 bp and -150 bp relative to the transcription start site.[10] These HNF4α sites facilitate basal promoter activity and mediate interactions with nuclear receptors such as constitutive androstane receptor (CAR) and pregnane X receptor (PXR) for inducible expression.[10] CYP2C9 demonstrates evolutionary conservation across mammalian species, highlighting its preserved role in metabolic functions.[11] In mice, for example, Cyp2c29 shares sequence similarity and structural features with human CYP2C9, including comparable exon-intron organization.[12] This supports the use of murine models for studying CYP2C9-related pathways.[12]

Tissue Distribution and Regulation

CYP2C9 is predominantly expressed in the liver, where it constitutes approximately 20% of the total hepatic cytochrome P450 (CYP) protein content, as determined by mass spectrometry-based quantitation.[2] This enzyme is also expressed in the small intestine, particularly the duodenum and jejunum, contributing to local drug metabolism in the gastrointestinal tract.[10] Lower levels of expression are observed in extrahepatic tissues, including the kidney, lung, and brain, reflecting its broader but secondary role in these sites.[10] Transcriptional regulation of CYP2C9 is primarily mediated by nuclear receptors such as the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR), which bind to specific response elements in the gene's promoter to activate expression in response to ligands.[10] These receptors enable adaptive responses to xenobiotics, with CAR particularly responsible for inducing CYP2C9 transcription through direct promoter interactions.[13] Peroxisome proliferator-activated receptor alpha (PPARα) exhibits cross-talk with CAR, influencing CYP2C9 regulation indirectly via shared signaling pathways in hepatic cells.[14] Post-transcriptional regulation involves microRNAs that target the 3'-untranslated region of CYP2C9 mRNA, leading to its degradation or translational repression; for instance, miR-130b directly downregulates CYP2C9 expression during inflammatory conditions.[15] Epigenetic modifications, such as DNA methylation in the promoter region, contribute to variable CYP2C9 expression levels across individuals, with hypomethylation associated with higher transcriptional activity in hepatic tissues.[16] Environmental factors, including certain drugs, induce CYP2C9 expression through activation of CAR and PXR pathways; rifampicin and phenobarbital are notable inducers that increase CYP2C9 mRNA and protein levels in human hepatocytes, enhancing metabolic capacity.[17] This induction mechanism allows CYP2C9 to respond to chemical exposures, though the extent varies by inducer concentration and individual factors.[18]

Protein Structure and Function

Protein Characteristics

The CYP2C9 enzyme is a hemoprotein belonging to the cytochrome P450 superfamily, characterized by a mature polypeptide chain of 490 amino acids and a calculated molecular weight of approximately 55.6 kDa.[5] It incorporates a heme prosthetic group at its active site, which coordinates to a conserved cysteine residue (Cys476) and facilitates electron transfer during catalysis.[19] Key residues within the active site, such as Arg108 and Phe114, contribute to substrate recognition and positioning; Arg108 forms hydrogen bonds that stabilize anionic substrates, while Phe114 influences the hydrophobic environment near the heme.[19][20] The crystal structure of unliganded CYP2C9, resolved at 2.6 Šresolution (PDB entry 1OG2), reveals a typical P450 fold with alpha-helical domains surrounding the heme, including a substrate-binding pocket accessed via a channel above the heme plane.[21] This pocket forms a relatively large cavity with a volume of approximately 1000 ų, accommodating diverse substrates through hydrophobic interactions and polar contacts.[19][22] CYP2C9 exhibits potential for oligomerization in solution, forming homo- or hetero-oligomers that may influence stability and activity.[23] Additionally, the enzyme anchors to the endoplasmic reticulum membrane via an N-terminal transmembrane helix, positioning the catalytic domain peripherally for interaction with redox partners.[24]

General Catalytic Activity

CYP2C9 functions as a heme-thiolate monooxygenase, catalyzing the insertion of one oxygen atom from molecular O₂ into a substrate while reducing the second oxygen atom to water, in an NADPH-dependent manner. This activity requires electron transfer from NADPH via cytochrome P450 oxidoreductase (POR), which docks to CYP2C9 and delivers the two electrons essential for oxygen activation. The enzyme's heme prosthetic group coordinates these processes, enabling the oxidative metabolism of diverse substrates with high regio- and stereospecificity.[25][26] The catalytic cycle of CYP2C9 follows the canonical cytochrome P450 mechanism. It initiates with substrate binding to the low-spin ferric (Fe³⁺) heme, often displacing a water ligand and shifting to a high-spin state that lowers the reduction potential for the first electron transfer from POR, yielding ferrous (Fe²⁺) heme. Molecular oxygen then binds to form a ferrous-dioxygen complex, followed by delivery of the second electron (from POR or cytochrome b₅), protonation, and formation of a hydroperoxo-ferric intermediate. Heterolytic cleavage of the O-O bond, facilitated by proton shuttling through a conserved acidic aspartate-threonine motif in the I-helix, generates the reactive Compound I species—a porphyrin π-cation radical paired with an oxo-iron(IV) (Fe(IV)=O) unit. Compound I performs the oxidative chemistry by abstracting a hydrogen atom from the substrate to form a short-lived carbon radical, which rebounds with the iron-bound oxygen to yield the hydroxylated product and regenerate the resting ferric state. This cycle consumes one equivalent each of NADPH and O₂ per turnover, ensuring efficient monooxygenation.[27][26] Kinetic parameters such as the Michaelis constant (Kₘ) and maximum velocity (Vₘₐₓ) reflect CYP2C9's substrate affinity and catalytic efficiency, varying modestly across expression systems but providing insight into its performance. Representative values from recombinant human CYP2C9 systems include:
SubstrateKₘ (μM)Vₘₐₓ (nmol/min/nmol P450)
Diclofenac (4'-hydroxylation)5.129
(S)-Warfarin (7-hydroxylation)4.62.33
Tolbutamide (methyl hydroxylation)10310.1
(S)-Flurbiprofen (4'-hydroxylation)16.234
These parameters indicate micromolar affinities for many acidic xenobiotics and turnover rates supporting physiological clearance rates, with intrinsic clearance (Vₘₐₓ/Kₘ) often highest for diclofenac and flurbiprofen.[28] CYP2C9 exhibits stereoselectivity in hydroxylation reactions, particularly at chiral centers, due to its active site's hydrophobic pocket and Arg108/Asn204 residues that favor binding of specific enantiomers. For instance, in ibuprofen metabolism, CYP2C9 preferentially hydroxylates the (S)-enantiomer at the 2- and 3-positions, with efficiency ratios (Vₘₐₓ/Kₘ) approximately 1.5- to 2-fold higher for (S)-ibuprofen compared to the (R)-form, reflecting enantiofacial discrimination during hydrogen abstraction. Similar stereopreference is observed for (S)-warfarin and (S)-phenytoin, where CYP2C9 catalyzes 7- and 4'-hydroxylation with greater velocity for the S-enantiomers, influencing the pharmacokinetics of chiral drugs. This selectivity arises from differential orientation of the chiral substrate relative to the reactive Compound I, ensuring targeted oxidation.[29][30]

Metabolic Roles

Endogenous Substrate Metabolism

CYP2C9 plays a significant role in the metabolism of endogenous steroid hormones via regioselective hydroxylation, aiding in their inactivation and clearance to maintain hormonal balance. It catalyzes the 6β-hydroxylation of testosterone, a primary androgen, which introduces a hydroxyl group at the 6β position of the steroid ring, facilitating further conjugation and elimination.[31] This activity has been observed in recombinant CYP2C9 systems, where wild-type and variant forms exhibit measurable rates of testosterone 6β-hydroxylation, underscoring its contribution to androgen homeostasis.[31] Similarly, CYP2C9 mediates the 6β-hydroxylation of progesterone, a key progestogen involved in reproductive physiology, thereby regulating its bioavailability and preventing excessive accumulation.[31] Beyond steroids, CYP2C9 contributes to retinoid metabolism, particularly through the 4-hydroxylation of all-trans-retinoic acid (ATRA), the active metabolite of vitamin A essential for embryonic development, vision, and immune function. This oxidative step converts ATRA to 4-hydroxy-ATRA, initiating its breakdown and modulating retinoid signaling pathways by limiting receptor activation. Studies using human liver microsomes and expressed enzymes have identified CYP2C9 as one of the isoforms supporting ATRA 4-hydroxylation, with kinetic parameters indicating moderate catalytic efficiency compared to CYP2C8.[32] This process helps fine-tune vitamin A homeostasis, preventing retinoid toxicity while supporting physiological signaling.[32] CYP2C9 also participates in endogenous fatty acid oxidation, exemplified by its hydroxylation of lauric acid, a medium-chain saturated fatty acid. It primarily performs 11-hydroxylation (ω-1 position) of lauric acid, producing 11-hydroxylauric acid as an intermediate in lipid catabolism. Kinetic analyses of CYP2C9 variants have confirmed this activity, with variations in Vmax and Km highlighting differences in efficiency but affirming the enzyme's role in processing dietary and endogenous fatty acids for energy homeostasis.[33]

Xenobiotic and Drug Metabolism

CYP2C9 plays a pivotal role in the phase I metabolism of numerous xenobiotics, particularly therapeutic drugs, by catalyzing oxidative reactions that convert lipophilic substrates into more water-soluble metabolites, facilitating their elimination and often reducing pharmacological activity. This enzyme accounts for approximately 15-20% of hepatic drug clearance through phase I processes in humans.[7][34] Among its substrates, CYP2C9 is essential for the detoxification of several clinically significant medications, where the resulting metabolites are typically inactive, thereby modulating drug efficacy and safety profiles. A prominent example is the anticoagulant warfarin, where CYP2C9 primarily metabolizes the more potent S-enantiomer via 7-hydroxylation to 7-hydroxywarfarin, an inactive metabolite that is subsequently conjugated and excreted. This reaction is critical for controlling warfarin's narrow therapeutic index, as impaired metabolism can lead to excessive anticoagulation. Similarly, CYP2C9 contributes to the metabolism of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, through hydroxylation to form 2-hydroxyibuprofen, a major inactive metabolite, and naproxen via O-demethylation to 6-O-desmethylnaproxen, which exhibits reduced anti-inflammatory activity.[7][35][36] CYP2C9 also metabolizes sulfonylureas used in diabetes management, including glipizide, primarily through aromatic hydroxylation to hydroxylated derivatives that possess diminished hypoglycemic potency and are more readily cleared. These phase I transformations underscore CYP2C9's detoxication function in xenobiotic handling, preventing accumulation of active parent compounds. Genetic variants in the CYP2C9 gene can significantly alter the metabolism rates of these substrates, influencing drug dosing and risk of adverse effects.[37]

Epoxygenase Pathway

Arachidonic Acid Epoxidation

CYP2C9, a member of the cytochrome P450 family, plays a key role in the epoxygenase pathway by catalyzing the NADPH-dependent monooxygenation of arachidonic acid, inserting an oxygen atom across one of its double bonds to form epoxyeicosatrienoic acids (EETs). This enzymatic reaction produces four potential regioisomers—5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET—but CYP2C9 exhibits regioselectivity, primarily generating 8,9-EET, 11,12-EET, and 14,15-EET in a ratio of approximately 0.5:1.0:2.3, respectively, with minimal formation of 5,6-EET.[38][39] The enzyme shows a marked preference for epoxidation at the terminal double bond, favoring the production of 14,15-EET, which constitutes the majority of EETs generated by CYP2C9. This regioselectivity is accompanied by stereospecificity, yielding predominantly the (14R,15S)-enantiomer of 14,15-EET with an optical purity of about 63%, and the (11S,12R)-enantiomer of 11,12-EET with around 69% optical purity.[38] The reaction mechanism involves the transfer of electrons from NADPH via cytochrome P450 reductase to the heme iron in CYP2C9, activating molecular oxygen for the epoxide formation.[40] CYP2C9's epoxygenase activity toward arachidonic acid is selectively inhibited by sulfaphenazole, a compound that binds to the enzyme's active site and reduces EET production, thereby blocking downstream effects mediated by these metabolites.[41] The EETs produced are labile and primarily metabolized by soluble epoxide hydrolase (sEH), which hydrolyzes the epoxide ring to form the corresponding dihydroxyeicosatrienoic acids (DHETs), with 14,15-EET serving as the preferred substrate for this degradation.[38] These EETs contribute to various vascular and anti-inflammatory functions, as explored in subsequent sections.[41]

Physiological and Pathophysiological Roles

The epoxyeicosatrienoic acids (EETs) produced by CYP2C9 exert vasodilatory effects primarily through activation of transient receptor potential vanilloid 4 (TRPV4) channels in vascular endothelial cells. This activation facilitates calcium influx, which subsequently stimulates large-conductance calcium-activated potassium (BKCa) channels, leading to endothelial hyperpolarization that propagates to vascular smooth muscle cells, promoting relaxation and vasodilation. This mechanism contributes to endothelium-dependent hyperpolarization and is crucial for regulating vascular tone in response to shear stress and hypotonic stimuli, as demonstrated in studies of resistance arteries and human coronary arterioles.[42][43] EETs exhibit anti-inflammatory properties by inhibiting nuclear factor-kappaB (NF-κB) activation in macrophages and endothelial cells, thereby reducing pro-inflammatory cytokine production and macrophage infiltration into inflamed tissues, though CYP2C9 may have distinct effects via superoxide generation. These effects support cardioprotection during ischemia-reperfusion injury, where EETs diminish infarct size, preserve mitochondrial function, and activate prosurvival pathways such as PI3K/Akt, improving left ventricular recovery and limiting fibrosis post-ischemia. These effects have been observed in models of myocardial infarction, highlighting EETs' role in mitigating acute and chronic cardiac damage.[44][45] Pathophysiologically, disruptions in CYP2C9-mediated EET signaling are associated with hypertension, where reduced EET levels contribute to impaired vasodilation and elevated blood pressure, while augmentation of EETs via soluble epoxide hydrolase inhibition confers antihypertensive and renoprotective benefits. In diabetes, polymorphisms in CYP2C9 have been associated with increased susceptibility to type 2 diabetes mellitus in certain populations, such as Chinese, though elevated EET signaling may ameliorate vascular complications by enhancing insulin sensitivity and reducing inflammation.[46] Conversely, in cancer, upregulated CYP epoxygenases including CYP2C9 promote tumor progression through EET-driven enhancement of cell migration, invasion, and metastasis, as evidenced in breast and other human cancers.[47] Sex differences in CYP2C9 activity arise from hormonal regulation, with estrogen activating the enzyme via estrogen receptor α (ERα) ligands, leading to higher EET synthesis in vascular tissues of females compared to males. This estrogen-mediated upregulation, observed in both human and murine models, influences EET-dependent vasodilation and may contribute to observed sex biases in cardiovascular protection.[48][49]

Pharmacogenomics and Clinical Relevance

Genetic Variants and Alleles

The CYP2C9 gene exhibits significant polymorphism, with over 80 star () alleles defined by the Pharmacogene Variation (PharmVar) Consortium as of 2024, primarily involving single nucleotide variants (SNVs) in the coding and regulatory regions that alter enzyme function.[50] The reference allele, CYP2C91, encodes the wild-type protein with normal catalytic activity and serves as the baseline for variant classification.[50] Among the most common variants, CYP2C92 (rs1799853, c.430C>T, p.Arg144Cys) results in moderately reduced enzyme activity, typically 50-70% of wild-type levels in vitro, due to impaired interaction with its electron donor, cytochrome P450 oxidoreductase (POR).[51][52] This allele has a global frequency of approximately 14% in Caucasian populations, but it is much rarer in East Asians (0.5-1%) and Africans (0.5%).[51] CYP2C93 (rs1057910, c.1079A>C, p.Ile359Leu) causes a more severe reduction in activity, often 5-20% of wild-type, and is prevalent at 6-10% in Caucasians, with frequencies up to 15% in some South Asian subgroups but near absence (<1%) in East Asians.[51][50] Rare variants include CYP2C94 (rs56165452, c.1076T>C, p.Ile359Thr), which decreases activity to about 10-20% of wild-type and is more common in East Asian populations (3-6%) but rare (<1%) elsewhere, and CYP2C98 (rs7900194, c.449G>A, p.Arg150His), associated with reduced function (30-50% of wild-type) and higher prevalence in African ancestry groups (2-4%).[50][51][25] These alleles follow the PharmVar star nomenclature, which accounts for haplotype-specific combinations of SNVs.[50] At the molecular level, the p.Ile359Leu substitution in CYP2C93 disrupts a hydrophobic interaction network distant from the active site (approximately 15 Å away), leading to destabilization of the heme environment, reduced substrate binding affinity, and impaired catalysis, as revealed by crystallographic studies with substrates like losartan.[2] Similarly, the p.Arg144Cys change in CYP2C92 affects the protein's surface residues, hindering efficient electron transfer from POR and thereby lowering overall metabolic efficiency.[52] CYP2C9 displays considerable haplotype diversity, with suballeles such as 2A (core defining SNV only) and 3B (including additional upstream variants like -65C>T), reflecting combinations of up to 20 defining SNVs per haplotype in the PharmVar database.[50] Haplotype structure is influenced by linkage disequilibrium (LD) within the CYP2C cluster on chromosome 10, notably strong LD between CYP2C92 and CYP2C83 (r² > 0.9 in many populations), which can affect variant detection and functional predictions across the locus.[53] Moderate LD also exists with CYP2C19 variants, such as between wild-type CYP2C91 and CYP2C1917 in European ancestries.[54]

Metabolizer Phenotypes and Testing

CYP2C9 metabolizer phenotypes are determined by the combined activity of the two inherited alleles, quantified through an activity score (AS) system established by the Clinical Pharmacogenetics Implementation Consortium (CPIC). These phenotypes classify individuals based on their expected enzyme function: poor metabolizer (PM) for markedly reduced activity (AS 0–0.5), intermediate metabolizer (IM) for moderately reduced activity (AS 1–1.5), normal metabolizer (NM) for typical activity (AS 2), and rapid metabolizer (RM) or ultrarapid metabolizer (UM) for increased activity (AS >2, though extremely rare due to lack of established gain-of-function variants).[55][56] For example, the PM phenotype, such as in *3/*3 homozygotes, results in enzyme activity often below 10% of normal levels for key substrates, leading to prolonged drug exposure.[57] The IM phenotype, common in heterozygotes like *1/*2 or *1/*3, typically exhibits 30–70% of normal activity, while NM represents the majority of the population with full function.[34]
Metabolizer PhenotypeActivity Score (AS)Description of Enzyme Activity
Poor (PM)0–0.5Markedly reduced (<10% of normal for many substrates)
Intermediate (IM)1–1.5Moderately reduced (30–70% of normal)
Normal (NM)2Normal (100% reference activity)
Rapid/Ultrarapid (RM/UM)>2Increased (>100%, extremely rare)
Genetic testing for CYP2C9 focuses on genotyping key variant alleles to predict these phenotypes, with recommendations from the Association for Molecular Pathology (AMP) and College of American Pathologists (CAP) defining tiered panels that account for ancestry-specific variants. The core (tier 1) panel includes alleles *2, *3, *5, *6, *8, and *11, which account for most reduced-function variants across diverse ancestries and detect over 90% of PMs in many populations. For broader coverage, especially in African or admixed ancestries, tier 2 extends to *4, *7–*10, *12–*14, *16, *17, *19, *20, *24, *30, *33, *37, *39, *40, *46, *47, *49, *51, *53, *54, *59, *60, *62, *64, *65, *68, *69, *71, and *72, often using next-generation sequencing (NGS) for comprehensive detection. Common methods include targeted polymerase chain reaction (PCR)-based assays for high-frequency alleles like *2 and *3, or NGS for multiplexed variant calling, as endorsed by the U.S. Food and Drug Administration (FDA) for pharmacogenomic testing in contexts like warfarin therapy.[58] CPIC guidelines standardize variant interpretation by assigning functionality scores (e.g., 0 for no function in *3, 0.5 for decreased in *2) to compute the diplotype AS and assign the corresponding phenotype, facilitating clinical decision-making. Phenotypic assessment of CYP2C9 activity complements genotyping through in vivo probing with substrate drugs, measuring metabolic ratios or clearance to classify individuals empirically. Probe drugs include tolbutamide, where the urinary ratio of 4-hydroxy-tolbutamide to tolbutamide reflects enzyme activity, and S-warfarin, monitored via plasma clearance or hydroxy-warfarin formation, both selective for CYP2C9.[59] Other probes like flurbiprofen or losartan are used in research settings to correlate phenotype with genotype, though clinical phenotyping is less common than genotyping due to invasiveness and variability from environmental factors.[34] These approaches help validate predicted phenotypes, particularly in cases of rare variants or discordant results.[60]

Therapeutic Implications and Drug Interactions

CYP2C9 genetic variants significantly influence the pharmacokinetics of several clinically important drugs, necessitating genotype-guided dosing adjustments to optimize therapeutic outcomes and minimize adverse events. In particular, poor metabolizers (PMs) and intermediate metabolizers (IMs) exhibit reduced enzyme activity, leading to higher drug exposure and increased risk of toxicity for substrates like warfarin and nonsteroidal anti-inflammatory drugs (NSAIDs).[61][62] Warfarin, an anticoagulant primarily metabolized by CYP2C9, exemplifies the clinical relevance of these variants. PMs, such as those with CYP2C9*2/*2, *2/*3, or *3/*3 genotypes, require an initial dose reduction of 30-50% compared to normal metabolizers to avoid over-anticoagulation and bleeding risks, while IMs (*1/*2 or *1/*3) need a 10-30% reduction.[61] These adjustments are further refined by considering VKORC1 variants, which affect warfarin sensitivity independently of CYP2C9.[61] Implementing pharmacogenetic testing for CYP2C9 and VKORC1 has been shown to improve dosing accuracy and reduce international normalized ratio (INR) variability in clinical practice.[61] For NSAIDs, CYP2C9 variants heighten the risk of dose-dependent toxicities, particularly gastrointestinal and cardiovascular effects. Celecoxib, a selective COX-2 inhibitor metabolized predominantly by CYP2C9, warrants a 25-50% dose reduction in IMs and avoidance or use of the lowest effective dose (e.g., 100 mg/day) in PMs, with close monitoring for adverse effects due to prolonged half-life and elevated plasma concentrations.[62] Similar precautions apply to other CYP2C9 substrates like ibuprofen and flurbiprofen, where PMs face substantially increased toxicity risks, emphasizing the need for alternative analgesics when possible.[62] Drug interactions further amplify the impact of CYP2C9 variants on therapy. Inhibitors such as amiodarone and fluconazole potently suppress CYP2C9 activity, elevating warfarin levels and bleeding risk in a dose-dependent manner, particularly in IMs and PMs who already have diminished clearance.[63] Conversely, inducers like rifampin accelerate CYP2C9-mediated metabolism, reducing warfarin efficacy and requiring dose increases to maintain therapeutic INR, with effects persisting for days after discontinuation due to enzyme induction dynamics.[7] These interactions underscore the importance of monitoring and adjusting regimens in patients with CYP2C9 variants. Case studies highlight severe adverse events linked to CYP2C9 impairment. For instance, carriers of the CYP2C9*3 allele have experienced phenytoin hypersensitivity reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, following intravenous administration, attributed to reduced metabolism leading to toxic accumulation.[64] In one reported case, a homozygous *3/*3 patient developed DRESS shortly after phenytoin initiation, resolving upon discontinuation and supportive care.[64] CPIC guidelines recommend 20-50% dose reductions for phenytoin in IMs and PMs to mitigate such exposure-related toxicities, including hypersensitivity risks.[65]

References

  1. CYP2C9 cytochrome P450 family 2 subfamily C member 9 [ (human)]
  2. Pharmacogenomics of CYP2C9: Functional and Clinical ...
  3. Massively parallel characterization of CYP2C9 variant enzyme ...
  4. CYP2C9 gene: MedlinePlus Genetics
  5. an enzyme of major importance in human drug metabolism - NIH
  6. Clinical and toxicological relevance of CYP2C9: drug ... - PubMed
  7. Cytochrome P450 2C9-CYP2C9 - PMC - PubMed Central - NIH
  8. Insights into the Genetic Variations of Human Cytochrome P450 2C9
  9. The transcriptional regulation of the human CYP2C genes - PMC - NIH
  10. Computational Identification of the Paralogs and Orthologs of ... - MDPI
  11. MGI:103238 - cytochrome P450, family 2, subfamily c, polypeptide 29
  12. The nuclear receptors constitutive androstane receptor ... - PubMed
  13. PPARα Activation Suppresses Cytochrome P450 Induction Potential ...
  14. Inflammation-associated microRNA-130b down-regulates ... - PubMed
  15. Analysis of DNA methylation landscape reveals the roles of DNA ...
  16. Induction of human CYP2C9 by rifampicin, hyperforin, and ... - PubMed
  17. Induction of CYP2C Genes in Human Hepatocytes in Primary Culture
  18. https://www.jbc.org/article/S0021-9258(20
  19. CYP2C9 Amino Acid Residues Influencing Phenytoin Turnover and ...
  20. Crystal structure of human cytochrome P450 2C9 with bound warfarin - Nature
  21. Structure of Cytochrome P450 2C9*2 in Complex with Losartan - NIH
  22. Effects of polymorphic variation on the thermostability of ... - Nature
  23. Membrane Position of Ibuprofen Agrees with Suggested Access ...
  24. CYP2C9 - Cytochrome P450 2C9 - Homo sapiens (Human) - UniProt
  25. Mechanisms of Cytochrome P450-Catalyzed Oxidations - PMC - NIH
  26. [PDF] CYTOCHROME P450: Structure-Function
  27. Enzyme Source Effects on CYP2C9 Kinetics and Inhibition - NIH
  28. Regioselective and stereoselective metabolism of ibuprofen by ...
  29. difference in chiral preference of CYP2C9 and CYP2C19 - PubMed
  30. Metabolism of steroids by cytochrome P450 2C9 variants
  31. Identification of human cytochrome P450 isoforms that contribute to ...
  32. Identification and functional characterization of a new CYP2C9 ...
  33. Impact of genetic and non-genetic factors on hepatic CYP2C9 ...
  34. Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen
  35. CYP2C9 Polymorphism Influence in PK/PD Model of Naproxen and ...
  36. Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and ...
  37. Regio- and stereoselective epoxidation of arachidonic acid by ...
  38. Cytochrome P450 Epoxygenase Metabolism of Arachidonic Acid ...
  39. Cytochrome P4502C9-Derived Epoxyeicosatrienoic Acids Induce ...
  40. https://doi.org/10.1161/01.RES.0000187474.47805.30
  41. https://doi.org/10.1093/cvr/cvn207
  42. Epoxyeicosatrienoic acids and cardioprotection: the road to translation
  43. The ligands of estrogen receptor α regulate cytochrome P4502C9 ...
  44. Roles of CYP2C29 and RXRγ in vascular EET synthesis of female ...
  45. PharmVar
  46. Global distribution of functionally important CYP2C9 alleles and ...
  47. The R144C change in the CYP2C9*2 allele alters interaction of the ...
  48. Global variation in CYP2C8–CYP2C9 functional haplotypes - PMC
  49. Linkage disequilibrium between the CYP2C19*17 allele ... - PubMed
  50. Clinical Pharmacogenetics Implementation Consortium (CPIC ... - NIH
  51. Global distribution of functionally important CYP2C9 alleles and ...
  52. [XLS] Allele Function
  53. Annotation of CPIC Guideline for piroxicam and CYP2C9 - ClinPGx
  54. Table of Pharmacogenetic Associations - FDA
  55. CYP2C9 Genotype vs. Metabolic Phenotype for Individual Drug ...
  56. The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 ...
  57. CPIC® Guideline for Pharmacogenetics-Guided Warfarin Dosing
  58. CPIC® Guideline for NSAIDs based on CYP2C9 genotype
  59. Drug Interactions Affecting Oral Anticoagulant Use | Circulation
  60. DRESS after IV phenytoin associated with cytochrome P450 ...
  61. CPIC® Guideline for Phenytoin and CYP2C9 and HLA-B
User Avatar
No comments yet.